Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable

Trial Details

NCT ID
NCT05053607
Phase
NA
Sponsor
Pack Health
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Digital Health Coaching Program
  • Fitbit
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Age 18 or older
  • Diagnosis of relapsed/refractory multiple myeloma corresponding to the Food and Drug Administration (FDA) package insert for isatuximab-irfc (Sarcl…
  • Confirmed or planned treatment with intravenous isatuximab-irfc for relapsed/refractory multiple myeloma as standard-of-care therapy. Concurrent th…
  • Access to and willingness to use a smartphone or other device through which they can send and receive text messages, emails and/or access a mobile …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →